Alar Pharmaceuticals Inc. (TPEX: 6785)

Market Cap	9.15B
Revenue (ttm)	474.29M
Net Income (ttm)	400.72M
Shares Out	66.80M
EPS (ttm)	6.28
PE Ratio	21.81
Forward PE	238.26
Dividend	1.50 (1.09%)
Ex-Dividend Date	n/a

Volume	63,574
Open	136.50
Previous Close	140.00
Day's Range	136.50 - 140.50
52-Week Range	135.00 - 465.00
Beta	0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 3, 2025

About Alar Pharmaceuticals

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson’s disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founde...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 22
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6785